Skip to main content
Figure 6 | Breast Cancer Research

Figure 6

From: Podocalyxin enhances breast tumor growth and metastasis and is a target for monoclonal antibody therapy

Figure 6

Systemic treatment with antipodocalyxin antibody PODOC1 inhibits primary tumor development and metastasis to the lung. (A) Growth curve of tumors from mice treated intraperitoneally (i.p.) with 100 μg of isotype control (Iso) or antipodocalyxin monoclonal antibody (mAb) PODOC1 on day 14 and every 3 to 4 thereafter days until being killed on day 27 (n = 5; *P < 0.05 by two-way analysis of variance) (right). Orange stars indicate i.p. administration of antibody. (B) Weight (g) of tumors treated with either Iso or PODOC1. Representative photograph shows tumors treated with either Iso or PODOC1 (inset) (n = 5; *P = 0.05). (C) Number of red fluorescent protein (RFP)-positive tumor cells per 106 lung cells of mice with tumors treated i.p. with either Iso or PODOC1 as detected by flow cytometry (n = 5; *P < 0.05). The data shown are representative of two independent experiments.

Back to article page